Pacific Edge Ltd. 2025 AR2
The report details Pacific Edge's operational and financial performance for the fiscal year ended March 31, 2025. Despite facing Medicare coverage uncertainty in the US, the company achieved significant milestones, including the inclusion of its Cxbladder Triage test in the American Urological Association guidelines with a 'Grade A' evidence rating. Financially, Pacific Edge reported operating revenue of $21.8 million, down 8.6% from the previous year, and a net loss after tax of $29.9 million. On the sustainability front, the company completed its second greenhouse gas emissions inventory, achieving a 5.9% reduction in carbon intensity per test.
Company: Pacific Edge Ltd.
Sector: Manufacturing
Country: New Zealand
Year: 2025
Type: AR2
Pages: 116
Back to company
Pacific Edge Ltd.
Annual Report
The report details Pacific Edge's operational and financial performance for the fiscal year ended March 31, 2025. Despite facing Medicare coverage uncertainty in the US, the company achieved significant milestones, including the inclusion of its Cxbladder Triage test in the American Urological Association guidelines with a 'Grade A' evidence rating. Financially, Pacific Edge reported operating revenue of $21.8 million, down 8.6% from the previous year, and a net loss after tax of $29.9 million. On the sustainability front, the company completed its second greenhouse gas emissions inventory, achieving a 5.9% reduction in carbon intensity per test.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2025
Reporting Period
Apr 1, 2024 - Mar 31, 2025
Fiscal Year
2025
Published
Jun 30, 2025
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Assurance
Assurance Provider
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Women on Board
Women in Management
Workplace Fatalities
Employees